Acquisition of Deciphera Pharmaceuticals to acquire its pipeline and in-house sales capabilities in Europe and the United States
First written in FY2024. 5 of 8 entries say "Advanced", first in FY2025. Latest entry: 2026-07-31.
No other company in this theme has enough history to compare yet.
- 2026-07-31AdvancedEarnings
「Sales of Qinlock, a treatment for gastrointestinal stromal tumors (GIST) sold by Deciphera Pharmaceuticals, increased by ¥2.8 billion, or 31.5%, year on year to ¥11.7 billion due to further market penetration, while sales of Romvimza, a treatment for tenosynovial giant cell tumor (TGCT), increased by ¥3.1 billion, or 289.3%, year on year to ¥4.1 billion due to continued treatment of existing patients and expansion of the sales territory, including Europe.」
Higher sales of Deciphera Pharmaceuticals' products and the expansion of Romvimza's sales territory were reflected in first-quarter results. - FY2026AdvancedAnnual report
「Revenue from Qinlock, a treatment for gastrointestinal stromal tumors sold by Deciphera, increased by ¥12.9 billion, or 50.6%, from the previous consolidated fiscal year to ¥38.4 billion; the previous consolidated fiscal year included revenue for 9 months from July to March. Revenue from Romvimza, a treatment for tenosynovial giant cell tumor (TGCT), was ¥8.3 billion.」
Products acquired through the Deciphera transaction contributed to full-year sales, with QINLOCK generating ¥38.4 billion and ROMVIMZA ¥8.3 billion. Approval for ROMVIMZA was also obtained in Europe. - FY2026-H1AdvancedAnnual report
「Sales of QINLOCK, a treatment for gastrointestinal stromal tumors sold by Deciphera, increased by ¥10 billion year on year (123.3%) to ¥18.1 billion (the prior-year figure covered sales for 3 months, from July to September), while sales of ROMVIMZA, a treatment for tenosynovial giant cell tumor (TGCT), amounted to ¥2.8 billion. In September this year, approval was obtained in Europe for ROMVIMZA (DCC-3014), a CSF-1 receptor inhibitor…」
Following the acquisition of Deciphera, first-half sales of QINLOCK amounted to ¥18.1 billion and sales of ROMVIMZA to ¥2.8 billion, while European approval for ROMVIMZA was obtained. The products and overseas commercial capabilities acquired through the transaction are now being put into operation in concrete terms. - FY2025AdvancedAnnual report
「Using Deciphera as the base for our US and European operations, we will reorganize and consolidate the functions previously maintained in the US and the UK. This will enable us to further accelerate our global operations as an integrated Group.」
The policy of reorganizing and consolidating functions around Deciphera as the base for the US and European operations was set out following completion of the acquisition, marking a shift to the implementation phase for realizing the acquisition benefits. - FY2025-H1AchievedAnnual report
「Under this agreement, the acquisition of the company was completed on 11 June 2024 (US Eastern Time), making it our wholly owned subsidiary.」
The acquisition of Deciphera Pharmaceuticals, Inc., contracted in April 2024, was completed on 11 June 2024, making the company a wholly owned subsidiary. The milestone of completing the acquisition transaction itself can be confirmed. - FY2024First statedAnnual report
「Through this acquisition, the company will expand its solid tumor pipeline, and the acquisition of QINLOCK® and Vimseltinib is expected to increase group earnings over the short to medium term. It will also acquire Deciphera's development and sales capabilities in Europe and the US, strengthening its direct-sales structure in those markets.」
The acquisition agreement was signed in April 2024, and the acquisition of Deciphera was completed on 11 June 2024 for approximately US$2.4 billion. The transaction, which brought in QINLOCK®, Vimseltinib and development and sales networks in the US and Europe, can be independently identified for the first time as a measure to strengthen the pipeline and establish in-house sales operations in the US and Europe.